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Objective. Some patients with chronic inflam-
matory diseases such as rheumatoid arthritis (RA)
improve rapidly from anti–tumor necrosis factor (anti-
TNF) therapy. No sensitive markers are available that
might predict outcome of anti-TNF therapy. We un-
dertook this study to investigate the predictive value
of hypothalamic–pituitary–adrenal (HPA) axis hor-
mones for clinical improvement during anti-TNF
therapy.
Methods. An observational study in 23 RA pa-
tients was followed by a validation study in 38 RA
patients. The patients receiving anti-TNF antibodies
had no glucocorticoid treatment, and we measured
baseline serum levels of adrenocorticotropic hormone
(ACTH) and cortisol. Improvement during anti-TNF
antibody treatment was judged by the Disease Activity
Score in 28 joints (DAS28), and serum levels of
cortisol were measured at followup.
Results. The observational study demonstrated
that improvement in the DAS28 correlated negatively
with baseline serum levels of cortisol (R  0.520, P 
0.011) and the cortisol:ACTH ratio (R  0.700, P 
0.0002). In the longitudinal part of the study at fol-
lowup, those patients with good improvement and ini-
tially low serum levels of cortisol demonstrated an
increase of serum cortisol, in contrast to patients with
little or no improvement. Findings in the observational
study were supported by those in the validation study in
a group of RA patients with less inflammation (corre-
lation of improvement in the DAS28 with cortisol:ACTH
ratio: R  –0.320, P  0.025).
Conclusion. This is the first study in a human
ISRCTN 68762628. FDA: BL 125057 (adalimumab portion of
the studies).
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chronic inflammatory disease to demonstrate that
inflammation-induced TNF interferes with HPA axis
integrity, which is linked to the disease outcome. These
findings position the HPA axis centrally in the vicious
circle of perpetuation of chronic inflammation.
Prediction of success during anti–tumor necrosis
factor (anti-TNF) antibody therapy in chronic inflamma-
tory diseases such as rheumatoid arthritis (RA) is of
outstanding importance, because extremely high therapy
costs might be avoided and treatment efficacy should be
improved. Predictive parameters are useful for the cli-
nician and for pharmaceutical companies in order to
improve therapy in chronic longstanding inflammatory
diseases. However, no predictive markers are currently
available that might help to guide decision making
before anti-TNF antibody treatment. Such a predictive
parameter should be accessible and measurable. It is
expected that an identified predictive marker for success
of anti-TNF therapy might also play an important role in
the pathophysiology of these diseases.
In recent years, the roles of hormones and the
peripheral nervous system have been investigated in the
pathophysiology of chronic inflammatory diseases such
as RA (1). In an animal model of arthritis, seminal work
at the beginning of the 1990s has positioned the
hypothalamic–pituitary–adrenal (HPA) axis centrally in
chronic inflammation (2). However, findings of those
studies have never been confirmed in patients with RA.
At present, it is still not known whether the HPA axis
really plays a central role in the perpetuation of the
chronic inflammatory process in RA. Although we rec-
ognize the important antiinflammatory and antierosive
roles of endogenous glucocorticoids in RA (3–5), we do
not exactly know whether a disease-related increase of
circulating TNF via a deterioration of the HPA axis can
add to the destructive process.
The role of circulating or locally produced TNF
as a factor influencing the human HPA axis has recently
been reviewed (6). TNF seems to be an important factor
in establishing a milieu with inadequately low cortisol
and adrenocorticotropic hormone (ACTH) secretion in
relation to ongoing inflammation (6). However, it is not
known whether TNF-induced inhibition of adrenal
glands leading to inadequate cortisol levels has any
impact on the chronic disease process.
The aim of this study was to investigate whether
baseline levels of HPA axis hormones can predict im-
provement in RA. If such a hormone parameter exists,
its alteration might shed light on the pathophysiologic
roles of TNF and the HPA axis and how they interplay.
PATIENTS AND METHODS
Patients and healthy controls. This study consisted of
2 independent arms. In an observational part (study 1), 23
white RA patients were treated either with infliximab (10
mg/kg per intravenous infusion on day 0 and at weeks 2, 6, and
10; n  7 in Erlangen, Germany) or with adalimumab (40 mg
per subcutaneous [SC] injection on day 0 and at weeks 2, 4, 6,
8, and 10; n  16 in Milan, Italy). In a second, validation study
(study 2), 38 white RA patients in Amsterdam, The Nether-
lands were treated with adalimumab (40 mg per SC injection
on day 0 and at weeks 2, 4, 6, 8, 10, 12, and 14). All patients had
longstanding RA fulfilling the 1987 revised criteria of the
American College of Rheumatology (ACR; formerly, the
American Rheumatism Association) (7). Initially, these pa-
tients were included in multicenter, double-blind, placebo-
controlled, randomized anti-TNF antibody studies (8,9). From
those studies, clinical data and patient samples were available
in order to retrospectively study aspects of the endocrine
system. The characteristics of patients are shown in Table 1.
The respective parts of the study involving infliximab and
adalimumab were approved by the Ethics Committees of the
University of Erlangen–Nuremberg, Erlangen, Germany, the
University Hospital L. Sacco, Milan, Italy, and the Academic
Table 1. Characteristics of the study subjects*
RA patients
Study 1
(n  23)
Study 2
(n  38)
Age, mean  SEM years 51.0 2.8 50.9  2.0
No. of women/no. of men
(% women/% men)
20/3 (87/13) 30/8 (79/21)
DAS28 at baseline (points),
mean  SEM
5.8  0.2† 5.4 0.2
ESR at baseline, mean 
SEM mm/hour
35.0  4.4‡ 23.8 3.0
IL-6 level at baseline,
mean  SEM pg/ml
27.6  6.2§ 15.2 3.8
Medication, no. (%)
Prednisolone 0 0
Infliximab 7 0
Adalimumab 16 38
Methotrexate 22 28
NSAIDs 21 (91)¶ 24 (63)
Methotrexate dosage,
mean  SEM mg/day
10.5  1.0# 18.6  1.2
Duration of anti-TNF
therapy, mean weeks
12 16
* There were 35 healthy subjects with a mean SEM age of 51.3 2.4
years. Twenty-six of these subjects (74%) were women and 9 (26%)
were men. RA  rheumatoid arthritis; DAS28  Disease Activity
Score in 28 joints; ESR  erythrocyte sedimentation rate; IL-6 
interleukin-6; NSAIDs  nonsteroidal antiinflammatory drugs; anti-
TNF  anti–tumor necrosis factor.
† P  0.065 versus patients in study 2.
‡ P  0.036 versus patients in study 2.
§ P  0.078 versus patients in study 2.
¶ P  0.01 versus patients in study 2.
# P  0.001 versus patients in study 2.
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Medical Center, University of Amsterdam, Amsterdam, The
Netherlands.
Clinical investigation, blood samples, and laboratory
parameters. Clinical improvement was calculated according to
the following formula: improvement (%)  100  (1 –
[DAS28followup/DAS28baseline]), where DAS28  Disease Ac-
tivity Score in 28 joints (10). For both types of anti-TNF
antibodies, detailed efficacy assessments including ACR and
European League Against Rheumatism response criteria have
been reported elsewhere, and they are not reported here (8,9).
Blood was obtained between 7:30 AM and 10:30 AM on
day 0 and at followup. We used radioimmunometric assays for
the quantitative determination of serum levels of cortisol
(Coulter Immunotech, Marseilles, France). Serum levels of
17-hydroxyprogesterone (IBL, Hamburg, Germany) and se-
rum levels of interleukin-6 (IL-6) (Quantikine; R&D Systems,
Minneapolis, MN) were measured by enzyme-linked immu-
nosorbent assay.
Using a sensitive enzyme immunoassay for ACTH
(detection limit 0.1 pmole/liter; Sangui BioTech, Santa Ana,
Figure 1. Interrelationship between clinical improvement during anti–tumor necrosis factor therapy and levels of inflammatory markers (A and B)
or hormones (C–E) measured at baseline in the observational study (study 1). Graphs depict linear regression lines as well as Pearson correlation
coefficients and their P values. In C–E, mean hormone levels of healthy subjects are represented by solid horizontal lines. Dotted horizontal lines
represent the 95% confidence interval of the mean. NS  not significant; DAS28  Disease Activity Score in 28 joints; IL-6  interleukin-6;
ACTH  adrenocorticotropic hormone; 17OH-progesterone  17-hydroxyprogesterone.
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CA, via IBL), we were able to demonstrate a highly significant
interrelationship between ACTH measured in serum and
ACTH assayed in plasma with the following regression equa-
tion: ACTH (plasma)  7.2508  1.8707  ACTH (serum)
(R  0.646, P  0.000001; n  112 healthy subjects) (11). In
the present study, we measured ACTH in the serum samples
Figure 2. Interrelationship between clinical improvement during anti–tumor necrosis factor therapy and molar hormone ratios measured at baseline
in the observational study (study 1). A and B, Molar ratio of serum cortisol:serum ACTH (A) and molar ratio of serum cortisol:serum
17-hydroxyprogesterone (B). Graphs depict linear regression lines as well as Pearson correlation coefficients and their P values. C, Box plots showing
the interrelationship between clinical improvement and the molar ratio of serum cortisol:serum ACTH measured at baseline. Each box represents
the 25th to 75th percentiles. Lines outside the boxes represent the 10th and the 90th percentiles. Lines inside the boxes represent the median. Values
in parentheses are the number of patients in each group. Medians of nonresponders (improvement in the DAS2820%,30%,40%, and50%)
and responders (improvement in the DAS28 20%, 30%, 40%, and 50%) were compared by t-test, and respective P values are shown. In all
panels, mean molar ratios in healthy subjects are represented by solid horizontal lines. Dotted horizontal lines represent the 95% confidence interval
of the mean. See Figure 1 for definitions.
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from healthy controls and patients with RA and reactive
arthritis using this enzyme immunoassay. Intraassay and inter-
assay coefficients of variation for all of the abovementioned
tests were 10%.
Statistical analysis. Differences of group means were
compared by t-test after investigation of variances in the 2
groups with the Levine test (SPSS/PC, Advanced Statistics,
V15; SPSS, Chicago, IL). The interrelationship between 2
parameters was tested by Pearson correlation analysis (SPSS).
In order to find a critical cutoff value for the ratio of serum
cortisol:serum ACTH, which can predict clinical improvement
using the DAS28, a receiver operating characteristic (ROC)
analysis was carried out (SPSS). The ROC analysis provided
the positive predictive value in order to predict the percentage
of patients with clinical improvement (20%, 30%, 40%, and
50% improvement). P values less than 0.05 were considered
significant.
As expected, the studied readout parameters in the
observational study (study 1) did not differ significantly be-
tween the patient group receiving infliximab and the patient
group receiving adalimumab. Thus, we did not further stratify
the patient groups for statistical analyses in the observational
study (study 1).
RESULTS
Observational study (study 1): baseline inflam-
matory markers and hormone levels in relation to
clinical improvement. Neither baseline serum levels of
C-reactive protein (CRP) nor baseline serum levels of
IL-6 were related to clinical improvement (Figures 1A
and B). In patients with good clinical improvement,
baseline serum levels of ACTH were significantly higher
compared with those in patients without improvement
(Figure 1C). Baseline serum levels of ACTH were lower
in RA patients than in healthy controls (Figure 1C). In
contrast, patients with high improvement in the DAS28
during anti-TNF therapy had normal to low baseline
levels of cortisol, whereas patients with little or no
improvement demonstrated markedly higher baseline
serum levels of cortisol (Figure 1D). Baseline serum
levels of 17-hydroxyprogesterone were independent of
clinical improvement and were somewhat lower than
those in healthy subjects (Figure 1E).
The molar ratio of serum cortisol to serum
ACTH was tightly regulated in healthy subjects (Figure
2A). This ratio measured at baseline was inversely
related to clinical improvement at followup (Figure 2A).
Those patients with good improvement demonstrated
near-normal values, whereas patients without improve-
ment or even worsening under anti-TNF therapy dem-
onstrated a high molar ratio (Figure 2A). Similarly, the
baseline molar ratio of serum cortisol to serum 17-
hydroxyprogesterone was near normal in clinically im-
proved patients and was higher in patients with little or
no improvement (Figure 2B).
Observational study (study 1): prediction of clin-
ical improvement by baseline levels of adrenal hor-
mones. At each level of clinical improvement (from 20%
to 50%), patients who responded to treatment (with
clinical improvement20%,30%,40%, and50%)
demonstrated a significantly lower molar ratio of serum
cortisol to serum ACTH measured at baseline than did
patients who did not respond to treatment (with clinical
improvement 20%, 30%, 40%, and 50%, respec-
tively) (Figure 2C). In order to determine a critical
cutoff value for the ratio of baseline serum cortisol to
baseline serum ACTH, which can distinguish between
responders and nonresponders, an ROC analysis was
performed. Depending on the degree of clinical im-
provement between 30%, 40%, and 50%, the cutoff
values for the ratio were 450,000, 221,200, and 196,000,
respectively. Using the respective cutoff value, one could
distinguish responders from nonresponders with positive
predictive values of 88%, 67%, and 80%, respectively
(e.g., the chance is 80% that a patient with a baseline
molar ratio 196,000 demonstrates a 50% improvement
during anti-TNF therapy).
We hypothesized that neutralization of TNF in-
creases endogenous cortisol secretion in patients with
good response. It turned out that serum cortisol levels
increased in patients with good improvement (32%
response rate), but they decreased in patients with little
or no improvement (Figure 3A). Patients with initially
low serum levels of cortisol and a marked cortisol
increase during anti-TNF therapy demonstrated good
improvement, in contrast to patients with initially high
cortisol levels and cortisol decrease during followup of
anti-TNF antibody treatment (Figure 3A). Improvement
in the DAS28 correlated significantly with the change in
serum cortisol level between baseline and followup
(Figure 3B). A similar phenomenon was not observed
with respect to the change in serum level of ACTH
between baseline and followup (Figure 3C).
Validation study (study 2): prediction of clinical
improvement by baseline levels of adrenal hormones. In
the validation study (study 2), it turned out that improve-
ment in the DAS28 was negatively correlated with the
ratio of serum cortisol to serum ACTH (Figure 4A).
Although this interrelationship was statistically signifi-
cant, it was not as strong as that in the observational arm
(compare with Figure 2A). However, patients in the
observational arm had significantly greater inflamma-
tion at baseline compared with patients in the validation
arm (Table 1).
In a further analysis, we combined data of pa-
tients in the 2 studies in order to investigate the com-
bined predictive importance of the ratio of serum corti-
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sol to serum ACTH (Figure 4B).This particular ratio
correlated negatively with improvement in the DAS28
(Figure 4B). In addition, patients with initially low
serum levels of cortisol and cortisol increase during
anti-TNF therapy demonstrated good improvement, in
contrast to patients with initially high cortisol levels and
Figure 3. Course of serum cortisol in individual patients during anti–tumor necrosis factor therapy in the observational study (study 1). A, Baseline
serum levels of cortisol, represented by colored circles, with colored lines indicating an increase (green) or decrease (red) between baseline and
followup. Mean serum levels of healthy subjects are represented by solid horizontal lines. Dotted horizontal lines represent the 95% confidence
interval of the mean. B, Interrelationship between improvement in the DAS28 and change in serum level of cortisol between baseline and followup.
The graph depicts the linear regression line as well as the Pearson correlation coefficient and its P value. Dotted horizontal line indicates no change
(no increase or decrease) in cortisol level. C, Interrelationship between improvement in the DAS28 and change in serum level of ACTH between
baseline and followup (there was no significant change). See Figure 1 for definitions.
Figure 4. Interrelationship between clinical improvement during anti–tumor necrosis factor (anti-TNF) therapy and hormonal changes. A, Molar
ratio of serum cortisol:serum ACTH in the validation study (study 2). B, Molar ratio of serum cortisol:serum ACTH in all patients in studies 1 and
2. In A and B, mean molar ratios in healthy subjects are represented by solid horizontal lines. Dotted horizontal lines represent the 95% confidence
interval of the mean. C, Course of serum cortisol in individual patients during anti-TNF therapy in all patients with rheumatoid arthritis in studies
1 and 2. Dotted horizontal line indicates no change (no increase or decrease) in cortisol level. Graphs depict linear regression lines as well as Pearson
correlation coefficients and their P values. See Figure 1 for other definitions.
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cortisol decrease during anti-TNF antibody treatment
(Figure 4C).
In order to determine a critical cutoff value for
the ratio of baseline serum cortisol to baseline serum
ACTH, which can distinguish between responders and
nonresponders, an ROC analysis was performed for the
combined data of study 1 and study 2. Depending on the
degree of clinical improvement between 30%, 40%, and
50%, the cutoff values were 449,915, 380,916, and
214,451, respectively. Using these cutoff values, one
could distinguish responders from nonresponders with
positive predictive values of 62%, 86%, and 90%, re-
spectively.
DISCUSSION
This is the first study to demonstrate an impor-
tant relationship between the baseline status of HPA
axis hormones as predictive parameters and clinical
improvement resulting from anti-TNF therapy in RA
patients. It turned out that a low ratio of baseline serum
cortisol to baseline serum ACTH (a marker of HPA axis
function) could reliably predict clinical improvement.
The findings of this study position the HPA axis, partic-
ularly the adrenal glands, centrally in RA pathophysiol-
ogy. Thus, our findings confirm the central role of the
HPA axis in RA as studied in a rat model of arthritis (2).
Assuming that an inflammatory process usually
up-regulates HPA axis function, cortisol levels are inap-
propriately normal in RA when cytokine levels are
highly increased (12–14). Secretion of cortisol and
ACTH is inadequately low in relation to serum levels of
proinflammatory cytokines such as IL-6 and TNF (15).
Only recently, the possibility of neutralizing distinct
proinflammatory cytokines such as TNF and IL-6 dem-
onstrated that these therapies can improve altered hor-
monal axes (6). TNF affects several important hormone-
converting enzymes in adrenocortical cells such as
P450scc, P450c17, and P450c21 (16,17). Thus, it seems
obvious that TNF interferes with normal integrity of the
HPA axis. However, it remains an open question
whether TNF-induced deterioration of the HPA axis has
any meaning for the ongoing inflammatory process and
for disease outcome.
Since this study demonstrated that RA patients
with low to normal serum levels of cortisol in relation-
ship to ACTH particularly respond to anti-TNF therapy,
which is accompanied by an increase of endogenous
cortisol, TNF-induced deterioration of adrenal function
most probably has an important effect on the disease
process. The molar ratio of serum cortisol to serum
ACTH is a marker of HPA axis function and integrity.
This ratio is tightly controlled under normal conditions
in healthy subjects. However, in patients with RA, this
ratio largely increases as a result of inadequate regula-
tory interactions of the hypothalamic–pituitary axis and
the adrenal glands. It seems as if the adrenal glands are
uncoupled from the hypothalamic–pituitary axis, leading
to normal to somewhat elevated cortisol levels but low
ACTH levels. The reason for this discrepancy might be
found in an activation of the adrenal gland independent
of ACTH (17). Cytokines such as IL-6 are able to
directly stimulate the adrenal glands (17). This might
Figure 5. Position of the hypothalamic–pituitary–adrenal (HPA) axis
in the pathophysiology of chronic inflammatory rheumatoid arthritis in
relation to tumor necrosis factor (TNF) and local joint inflammation.
A double vicious circle is demonstrated: 1) The disease is most
probably started by a shift of balance from the tolerant to the
aggressive side of an autoimmune response against a harmless antigen.
2) The immune response leads to clonal extension of T and/or B
lymphocytes with an autoaggressive phenotype. 3) These autoaggres-
sive cells start local tissue inflammation, which involves cell types such
as macrophages, fibroblasts, natural killer cells, and many others.
Local inflammation leads to spillover of TNF into the systemic
circulation. 4) A longstanding increase of circulating TNF inhibits the
entire HPA axis on several organ levels. Interestingly, serum cortisol
levels are somewhat increased, whereas adrenocorticotropic hormone
(ACTH) levels are significantly decreased. Nevertheless, the amount
of cortisol is inadequate in relation to ongoing inflammation. 5)
Endogenous cortisol would normally inhibit peripheral inflammation
in the joints and elsewhere. Since cortisol levels are inadequate,
inhibition of inflammation is insufficient. Insufficient suppression of
inflammation perpetuates the disease process. Some patients with
lower baseline serum levels of cortisol demonstrate good clinical
response and elevation of serum cortisol under anti-TNF therapy. In
this group of good responders, the TNF-induced brake on the HPA
axis seems to be particularly strong.
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lead to the observed increase of cortisol and low levels of
ACTH, resulting in an increased cortisol:ACTH ratio.
Furthermore, this study distinguishes 2 groups of
RA patients. The first group had relatively low baseline
serum levels of cortisol and a near-normal molar ratio of
cortisol to ACTH (on the right end of the x-axis in
Figure 2A). These patients were good responders and
their cortisol levels increased during anti-TNF therapy
(the green dots in Figure 3). The second group of
patients demonstrated high cortisol levels at baseline
and a high ratio of serum cortisol to serum ACTH (on
the left end of the x-axis in Figure 2A). This group of
patients showed a decrease of endogenous cortisol dur-
ing anti-TNF antibody treatment (the red dots in Figure
3).
At present, it is unclear why 2 types of RA
patients exist. It might be speculated that the TNF
influence on the HPA axis is remarkably different in the
2 groups. In one group (the nonresponders), TNF seems
to stimulate endogenous cortisol, and TNF neutraliza-
tion leads to a decrease of serum cortisol, which is
related to a lack of improvement in the DAS28. In the
other group (the responders), TNF seems to inhibit
adrenal cortisol secretion, and TNF neutralization leads
to an increase of serum cortisol, which is related to
improvement in the DAS28. It might be that genetic
prerequisites of TNF signaling or TNF-induced modu-
lation of hormone conversion enzymes and cofactors
might be critically different in responders compared with
nonresponders. Further studies are needed to investi-
gate this important possibility. The present study further
demonstrates that the HPA axis has an important inter-
mediate position in the vicious circle of RA pathophys-
iology (Figure 5).
In the comparison between the observational arm
(study 1) and the validation arm (study 2), it is obvious
that study 1 demonstrated a better predictive role of the
serum cortisol:serum ACTH ratio than did study 2.
Patients in study 2 had markedly less systemic inflam-
mation (as indicated by lower erythrocyte sedimentation
rate [ESR] and lower serum level of IL-6), which might
have been due to stricter control of disease with meth-
otrexate (a significantly higher dosage) (Table 1). Since
methotrexate can inhibit secretion of TNF, it might well
be that patients in study 2 had lower circulating levels of
TNF compared with patients in study 1 (TNF levels were
not measured due to interference from injected anti-
TNF antibodies). Although anti-TNF therapy might
inhibit TNF effects locally in the joint, the influence of
this therapy on the adrenal level might be less marked
due to lower circulating TNF levels. It needs to be
determined whether the initial proinflammatory status
as measured by ESR or other circulating markers of
inflammation can even improve prediction of success of
anti-TNF therapy.
In conclusion, in RA patients receiving anti-TNF
therapy, low baseline serum levels of cortisol and low
baseline cortisol levels in relation to ACTH predict
clinical improvement. It is likely that an anti-TNF–
mediated increase of serum cortisol plays an important
role in this phenomenon. The present study demon-
strated that a simple cortisol and ACTH measurement
can help to further guide anti-TNF antibody treatment.
This is particularly relevant because important para-
meters such as CRP level, ESR, and swollen joint count
are not predictive in RA patients treated with anti-TNF
antibodies plus methotrexate (18). We suggest that
inclusion of cortisol and ACTH and their respective
molar ratio in the decision-making process can help to
determine the appropriateness of anti-TNF therapy in
patients with RA.
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